. Author manuscript; available in PMC: 2019 Jan 1.

Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1–12. doi: 10.1016/j.clml.2017.11.008

Table 7.

Ongoing trials evaluating ruxolitinib combinations in patients with myelofibrosis.

Partner drug class	Specific agent	Clinicaltrials.gov identifier
Histone deacetylase inhibitor	Panobinostat	NCT01693601
	Panobinostat	NCT01433445
	Pracinostat	NCT02267278
Phosphatidylinositol-3-kinase (delta isoform) inhibitor	INCB050465	NCT02718300
	Idelalisib	NCT02436135
	TGR1202	NCT02493530
Immunomodulatory agent	Thalidomide	NCT03069326
	Lenalidomide	NCT01375140
	Pomalidomide	NCT01644110
Janus kinase 1 inhibitor	Itacitinib	NCT03144687
BH3-mimetic	Navitoclax	NCT03222609
Hedgehog (smoothened) inhibitor	Vismodegib	NCT02593760
Hedgehog (smoothened) inhibitor	Sonidegib	NCT01787552
Cyclin-dependent kinase 4/6 inhibitor and PIM kinase inhibitor	Ribociclib and PIM447	NCT02370706
Androgen	Danazol	NCT01732445
Interferon	Pegylated interferon alfa 2a	NCT02742324
Hypomethylating agent	Azacitidine	NCT01787487
Activin receptor ligand trap	Sotatercept	NCT01712308
Activin receptor ligand trap	Luspatercept	NCT03194542
Erythropoiesis stimulating agent	Any (observational study)	NCT03208803